Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 15/20 | 0.77 |
| ▸ | RAB9A | P51151 | 12/20 | 0.77 |
| ▸ | NPC1 | O15118 | 10/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559122 | 0.89 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2555802 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2554355 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2554100 | 0.86 | SMN1; SMN2 (0.80) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2558990 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2555807 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2557908 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2553528 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2554297 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 | |
| SCHEMBL2553764 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ANPC1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | claimed |
| WO-2011130515-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-20 | — | — | WO | claimed |
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011130515-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096160-A1 | ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION | SMN1; SMN2, MTPN, MORF4L1 | SMN1; SMN2 1/4885RAB9A 1682/4885NPC1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.